Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.45 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.43 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.40 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.39 |
| ▸ | HTR5A known ✓ | P47898 | 2/20 | 0.39 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30142485 | 1.00 | PYGL (0.48) | PYGLKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL29622425 | 0.98 | PYGL (0.49) | PYGLKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL3112268 | 0.98 | PYGL (0.49) | PYGLKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL5467312 | 0.92 | PYGL (0.45) | PYGLKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL30583047 | 0.86 | PARP10 (0.56) | PYGLMAPTALDH1A1PARP1PARP10 | |
| SCHEMBL549252 | 0.86 | PARP10 (0.56) | PYGLMAPTALDH1A1PARP1PARP10 | |
| Hydrochloric Acid SCHEMBL19926551 | 0.85 | MAPT (0.57) | PYGLKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL2216455 | 0.82 | MAPT (0.54) | PYGLKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL24286750 | 0.81 | PARP10 (0.42) | PYGLKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL24286751 | 0.81 | TDP2 (0.48) | PYGLKDM4EMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843379-B | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220315567-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | disclosed |
| CN-109843379-A | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-2519505-B1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2015-05-27 | — | — | EP | disclosed |
| US-8729098-B2 | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM SA (LU) | 2014-05-20 | — | — | US | disclosed |
| US-20120309751-A1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2012-12-06 | — | — | US | disclosed |
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2519505-A1 | NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | Polichem SA (LU) | 2012-11-07 | — | — | EP | disclosed |
| CN-102686566-A | Novel tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM SA | 2012-09-19 | — | — | CN | disclosed |
| EP-2356094-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2345643-A1 | New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM S.A. (LU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011080264-A1 | NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM S.A. (LU) | 2011-07-07 | — | — | WO | disclosed |
| WO-2010049302-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309751-A1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | TUBA8, SUCLG1, TUBB8 | GAA 395/4885PARP1 2129/4885HRH3 295/4885 |
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | GAA 1805/4885PARP1 2953/4885HRH3 1751/4885 |
| US-20220315567-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | GAA 1805/4885PARP1 2953/4885HRH3 1751/4885 |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | UMPS, METTL3, UTS2R | GAA 1805/4885PARP1 2953/4885HRH3 1751/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | GAA 1805/4885PARP1 2953/4885HRH3 1751/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | GAA 1805/4885PARP1 2953/4885HRH3 1751/4885 |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | GPBAR1, GPR119, GLP1R | GAA 1013/4885PARP1 1728/4885HRH3 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.